アブストラクト
Japanese
| Title | セフメタゾールの臨床的有効用量とGiusti-Hayton法による用量調節の妥当性の検討 |
|---|---|
| Subtitle | 一般論文 |
| Authors | 陳内博之1, 豊田真史2, 安藤志帆3, 五十嵐玲子1 |
| Authors (kana) | |
| Organization | 1東京都保健医療公社荏原病院薬剤科, 2東京都保健医療公社豊島病院薬剤科, 3東京都保健医療公社東部地域病院薬剤科 |
| Journal | 医療薬学 |
| Volume | 48 |
| Number | 2 |
| Page | 79-86 |
| Year/Month | 2022 / 2 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」 セフメタゾール(cefmetazole : CMZ)はグラム陽性菌, グラム陰性菌, 嫌気性菌に抗菌活性を有する一方で緑膿菌などのブドウ糖非発酵菌に対する抗菌活性がないため, 軽症から中等症の腹腔内感染や尿路感染などの初期治療および起因菌判明後の標的治療として広く使用されている抗菌薬である. また, 基質特異性拡張型βラクタマーゼ産生菌に対する有効性が近年多く報告されていることから, このような一部の多剤耐性菌に対しても使用可能な抗菌薬である. 国外の成書では6g/日を常用量とする記載もあるが, 国内の添付文書(セフメタゾン(R), アルフレッサファーマ株式会社, 2019年3月改定)では2g/日を基本用量とし, 最大4g/日までの増量しか認められていない. そのため, 国内での使用においては最大4g/日の投与にとどめるべきであるが, 臨床的に有効なCMZの1日投与量を決定づける根拠に乏しいのが現状である. |
| Practice | 薬学 |
| Keywords | cefmetazole, dose, renal function, Giusti-Hayton method |
English
| Title | Examination of the Clinically Effective Dose of Cefmetazole and the Validity of Dose Adjustment Using the Giusti-Hayton Method |
|---|---|
| Subtitle | Regular Articles |
| Authors | Hiroyuki Jinnai1, Masashi Toyoda2, Shiho Ando3, Reiko Igarashi1 |
| Authors (kana) | |
| Organization | 1Department of Pharmacy, Ebara Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, 2Department of Pharmacy, Toshima Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, 3Department of Pharmacy, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 48 |
| Number | 2 |
| Page | 79-86 |
| Year/Month | 2022 / 2 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Cefmetazole (CMZ) is a widely used antimicrobial agent against various infectious diseases. Few studies have determined the appropriate daily dose, and the dose adjustment criteria based on renal function are unclear. Therefore, this study evaluated the clinically effective dose of CMZ and the validity of dose adjustment using the Giusti-Hayton (G-H) method. Patients who received CMZ at Ebara Hospital from April 2019 to March 2021 were included. The basic daily dose was set at 4g, which is the maximum dose approved in Japan, and a dose adjustment standard table was prepared with variables calculated using the G-H method. The patients were grouped according to whether their dosage of CMZ was adjusted using G-H method or not into the G-H and non-G-H groups. We set the primary endpoints as the efficacy and safety of CMZ, and the secondary endpoint as the pharmacokinetics/pharmacodynamics parameter (PK/PD parameter). There were 107 and 99 target cases in the G-H and non-G-H groups, respectively. The G-H group included several elderly people with a poor prognosis for infectious diseases; however, there was no significant difference in the efficacy and safety of CMZ between the groups. The time above MIC was significantly higher in the G-H group. Therefore, dose adjustment using the G-H method, based on a dose of 4g/day, can be useful in terms of PK/PD parameters. Moreover, it has been shown to be highly effective and safe. Thus, the results of this study may help in determining the dose and dose adjustment of CMZ. |
| Practice | Pharmaceutical sciences |
| Keywords | cefmetazole, dose, renal function, Giusti-Hayton method |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Jones RN, Barry AL, Fuchs PC, Thornsberry C, Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by diffusion, dilution, and anaerobic methods, J Clin Microbiol, 1986,24,1055-1059.
- 2) Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G, Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems, BMC Infect Dis, 2016,16,427.
- 3) Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S, Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia, Antimicrob Agents Chemother, 2015,59,5107-5113.
- 4) Kuwana T, Yamaguchi J, Kinoshita K, Hori S, Ihara S, Taniguchi T, Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series, Open Med (Wars), 2020,15,782-786.
- 5) Bennett JE, Dolin R, Blaser MJ, "Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases", ELSEVIER, Philadelphia, 2019,p277.
残りの18件を表示する
- 6) Halstenson CE, Guay DR, Opsahl JA, Hirata CA, Olanoff LS, Novak E, Ko H, Cathcart KS, Matzke GR, Disposition of cefmetazole in healthy volun-teers and patients with impaired renal function, Antimicrob Agents Chemother, 1990,34,519-523.
- 7) Borin MT, Peters GR, Smith TC, Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers, Antimicrob Agents Chemother, 1990,34,1944-1948.
- 8) Giusti DL, Hayton WL, Dosage regimen adjust-ments in renal impairment, Intel Clin Pharm, 1973,7,382-386.
- 9) 厚生労働省医薬・生活衛生局 医薬品審査管理課長通知, 抗菌薬の臨床評価方法に関するガイドライン, 日本化学療法学会雑誌, 2018,66,3-81.
- 10) 日本化学療法学会 抗微生物薬安全性評価基準検討委員会, 抗微生物薬安全性評価基準, 日本化学療法学会雑誌, 2010,58,484-493.
- 11) Lodise TP, Lomaestr BM, Drusano GL, Society of Infectious Disease Pharmacists: Application of anti-microbial pharmacodynamic concept into clinical practice:focus on beta-lactam antibiotics:insights from Society of Infectious Diseases Pharmacists, Pharmacotherapy, 2006,26,1320-1332.
- 12) Tomizawa A, Nakamura T, Komatsu T, Inano H, Kondo R, Watanabe M, Atsuda K, Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer, J Pharm Health Care Sci, 2017,3,1. doi:10.1186/s40780-016-0071-6.
- 13) Tan JS, Salstrom SJ, Signs SA, Hoffman HE, File TM, Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels, Antimicrob Agents Chemother, 1898,33,924-927.
- 14) 尾田一貴, モンテカルロシュミレーションに対応したMicrosoft(R) Office Excelによる抗菌薬のPK/PDシュミレーションソフトの開発, 医療薬学, 2011,37,335-344.
- 15) Brook I, Frazier EH, Aerobic and anaerobic micro-biology in intra-abdominal infections associated
- with diverticulitis, J Med Microbiol, 2000,49,827-830.
- 16) Czaja CA, Scholes D, Hooton TM, Stamm WE, Population-based epidemiologic analysis of acute pyelonephritis, Clin Infect Dis, 2007,45,273-280.
- 17) Owaki T, Okumura H, Uchikado Y, Sasaki K, Matsumoto M, Omoto I, Setoyama T, Kita Y, Sakurai T, Matsushita D, Ishigami S, Ueno S, Natsugoe S, Serum concentrations of antibiotics during severe invasive surgery such as esophagectomy for esopha-geal cancer, Int Surg, 2013,98,1-5.
- 18) Gavazzi G, Krause KH, Ageing and infection, Lancet Infect Dis, 2002,2,659-666.
- 19) Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KHDe Broe ME, The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure, Br J Clin Pharmacol, 1984,18,183-193.
- 20) Craig WA, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis, 1998,26,1-10.
- 21) MacVane SH, Kuti JL, Nicolau DP, Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation, Int J Antimicrob Agents, 2014,43,105-113.
- 22) Tawara S, Matsumoto S, Kamimura T, Goto S, Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics, Antimicrob Agents Chemother, 1992,36,17-27.
